Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.

Literature DB >> 33002129

Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.

Adam S Kittai^1,2,3, David A Bond^1,2,3, Basem William^1,2,3, Ayman Saad^1,2,3, Sam Penza^1,2,3, Yvonne Efebera^1,2,3, Karilyn Larkin^1,2,3, Sarah A Wall^1,2,3, Hannah K Choe^1,2,3, Bhavana Bhatnagar^1,2,3, Sumithira Vasu^1,2,3, Jonathan Brammer^1,2,3, Polina Shindiapina^1,2,3, Meixiao Long^1,2,3, Alice Mims^1,2,3, Lynn O'Donnell^1,2,3, Seema A Bhat^1,2,3, Kerry A Rogers^1,2,3, Jennifer A Woyach^1,2,3,4, John C Byrd^1,2,3,4, Samantha M Jaglowski^1,2,3.

Abstract

Entities: Species

Mesh：

Substances：

Year: 2020 PMID： 33002129 PMCID： PMC7556158 DOI： 10.1182/bloodadvances.2020002783

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

× No keyword cloud information.

14 in total

1. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors: Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245

2. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors: Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal: J Clin Oncol Date: 2017-07-17 Impact factor: 44.544

3. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors: Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245

4. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544

5. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8⁺ T cells and impede CAR T-cell efficacy.

Authors: Jaco A C van Bruggen; Anne W J Martens; Joseph A Fraietta; Tom Hofland; Sanne H Tonino; Eric Eldering; Mark-David Levin; Peter J Siska; Sanne Endstra; Jeffrey C Rathmell; Carl H June; David L Porter; J Joseph Melenhorst; Arnon P Kater; Gerritje J W van der Windt
Journal: Blood Date: 2019-05-10 Impact factor: 22.113

6. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.

Authors: Apostolia-Maria Tsimberidou; Susan O'Brien; Issa Khouri; Francis J Giles; Hagop M Kantarjian; Richard Champlin; Sijin Wen; Kim-Anh Do; Susan C Smith; Susan Lerner; Emil J Freireich; Michael J Keating
Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544

7. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors: Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal: Blood Date: 2016-01-26 Impact factor: 22.113

Review 8. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors: Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal: Biol Blood Marrow Transplant Date: 2018-12-25 Impact factor: 5.742

9. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors: Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal: Nat Med Date: 2018-04-30 Impact factor: 53.440

10. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.

Authors: Jim S Qin; Timothy G Johnstone; Alex Baturevych; Ronald J Hause; Seamus P Ragan; Christopher R Clouser; Jon C Jones; Rafael Ponce; Cecile M Krejsa; Ruth A Salmon; Michael O Ports
Journal: J Immunother Date: 2020-05 Impact factor: 4.912

15 in total

1. A phase two study of high dose blinatumomab in Richter's syndrome.

Authors: Philip A Thompson; Xianli Jiang; Pinaki Banerjee; Rafet Basar; Naveen Garg; Ken Chen; Mecit Kaplan; Vandana Nandivada; Ana Karen Nunez Cortes; Alessandra Ferrajoli; Michael J Keating; Christine B Peterson; Michael Andreeff; Katayoun Rezvani; William G Wierda
Journal: Leukemia Date: 2022-08-08 Impact factor: 12.883

2. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.

Authors: Alex F Herrera; Kwang Woo Ahn; Carlos Litovich; Yue Chen; Amer Assal; Qaiser Bashir; Ruthee-Lu Bayer; Melanie Coleman; Zachariah DeFilipp; Nosha Farhadfar; Matthew Greenwood; Theresa Hahn; Mitchell Horwitz; Caron Jacobson; Samantha Jaglowski; Sylvie Lachance; Amelia Langston; Bassam Mattar; Richard T Maziarz; Joseph McGuirk; Mohammad A H Mian; Sunita Nathan; Adrienne Phillips; Kevin Rakszawski; Henrik Sengeloev; Shalini Shenoy; Robert Stuart; Craig S Sauter; Mohamed A Kharfan-Dabaja; Mehdi Hamadani
Journal: Blood Adv Date: 2021-09-28

Review 3. CAR T-cell therapy for B-cell lymphoma.

Authors: Nathan Denlinger; David Bond; Samantha Jaglowski
Journal: Curr Probl Cancer Date: 2021-12-25 Impact factor: 2.367

Review 4. Richter's Transformation.

Authors: Audrey M Sigmund; Adam S Kittai
Journal: Curr Oncol Rep Date: 2022-04-06 Impact factor: 5.945

5. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.

Authors: Jun Meng; XiaoQin Wu; Zhen Sun; RenDe Xun; MengSi Liu; Rui Hu; JianChao Huang
Journal: Front Oncol Date: 2021-07-26 Impact factor: 6.244

6. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.

Authors: Haesook T Kim; Peter O Baker; Erin Parry; Matthew Davids; Edwin P Alyea; Vincent T Ho; Corey Cutler; John Koreth; Mahasweta Gooptu; Rizwan Romee; Sarah Nikiforow; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Catherine J Wu; Jennifer R Brown
Journal: Haematologica Date: 2021-12-01 Impact factor: 9.941

Review 7. Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners.

Authors: Sophia Stock; Anna-Kristina Kluever; Stefan Endres; Sebastian Kobold
Journal: Biomedicines Date: 2022-01-28

Review 8. Novel Approaches for the Treatment of Patients with Richter's Syndrome.

Authors: Andrea Iannello; Silvia Deaglio; Tiziana Vaisitti
Journal: Curr Treat Options Oncol Date: 2022-03-16

Review 9. Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors.

Authors: Razan Mohty; Jordan Gauthier
Journal: Bone Marrow Transplant Date: 2021-07-21 Impact factor: 5.174

10. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.

Authors: XiaoQin Wu; XinYue Zhang; RenDe Xun; MengSi Liu; Zhen Sun; JianChao Huang
Journal: Front Immunol Date: 2021-07-05 Impact factor: 7.561